• Home

  • Partners

  • Work Packages

  • News and Events

  • Intranet

  • Contact Us

  • Glossary

  • More

    SUrrogate markers for Micro- and Macro-vascular hard endpoints for Innovative diabetes Tools

    Navigation

    • Work Package (WP1)

    • Work Package (WP2)

    • Work Package (WP3)

    • Work Package (WP4)

    • Work Package (WP5)

    • Work Package (WP6)

    • Project Partners

    Work Packages

    SUMMIT has established an integrated framework of expertise involving ni-neteen European academic institutions, one SME (small and medium sized enterprises) along with six Pharma partners. The team combines compe-tencies from a wide range of disciplines including molecular and cellular biology, genetics, animal models, bioinformatics and imaging technologies.

         Retinopathy                   Nephropathy           Cardiovascular Disease

    © 2014 by IMI-SUMMIT. All rights reserved.

    Website design: Klodiana Jani

    MISSION

    T​o DISCOVER, DEVELOP and QUALIFY potential MARKERS that empower:

    ​

    • the identification of patients at high risk of diabetes complications

    • the monitoring of the complications' progression and patients‘ response to therapy 

    ​

    To use the discovered markers as SURROGATE ENDPOINTS in clinical trials.

    

    Thereby, SHORTEN the long lasting CLINICAL TRIALS to bring about EARLIER availability of NEW THERAPY to diabetic patients.

    Related Sites